Correlation Between Coya Therapeutics, and Cue Biopharma
Can any of the company-specific risk be diversified away by investing in both Coya Therapeutics, and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Coya Therapeutics, and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Coya Therapeutics, Common and Cue Biopharma, you can compare the effects of market volatilities on Coya Therapeutics, and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Coya Therapeutics, with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Coya Therapeutics, and Cue Biopharma.
Diversification Opportunities for Coya Therapeutics, and Cue Biopharma
0.61 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Coya and Cue is 0.61. Overlapping area represents the amount of risk that can be diversified away by holding Coya Therapeutics, Common and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Coya Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Coya Therapeutics, Common are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Coya Therapeutics, i.e., Coya Therapeutics, and Cue Biopharma go up and down completely randomly.
Pair Corralation between Coya Therapeutics, and Cue Biopharma
Given the investment horizon of 90 days Coya Therapeutics, is expected to generate 5.68 times less return on investment than Cue Biopharma. But when comparing it to its historical volatility, Coya Therapeutics, Common is 3.54 times less risky than Cue Biopharma. It trades about 0.11 of its potential returns per unit of risk. Cue Biopharma is currently generating about 0.18 of returns per unit of risk over similar time horizon. If you would invest 109.00 in Cue Biopharma on November 3, 2024 and sell it today you would earn a total of 36.00 from holding Cue Biopharma or generate 33.03% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 95.24% |
| Values | Daily Returns |
Coya Therapeutics, Common vs. Cue Biopharma
Performance |
| Timeline |
| Coya Therapeutics, Common |
| Cue Biopharma |
Coya Therapeutics, and Cue Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Coya Therapeutics, and Cue Biopharma
The main advantage of trading using opposite Coya Therapeutics, and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Coya Therapeutics, position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.| Coya Therapeutics, vs. Cue Biopharma | Coya Therapeutics, vs. Lantern Pharma | Coya Therapeutics, vs. Fennec Pharmaceuticals | Coya Therapeutics, vs. Acumen Pharmaceuticals |
| Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Anixa Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Complementary Tools
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| CEOs Directory Screen CEOs from public companies around the world |